期刊文献+

MRI对胰腺导管内乳头状粘液瘤良恶性的诊断价值 被引量:3

Diagnostic Value of MRI for Benign and Malignant Intraductal Papillary Myxoma of the Pancreas
下载PDF
导出
摘要 目的探讨MRI对胰腺导管内乳头状粘液性肿瘤(IPMN)良恶性的鉴别诊断价值。方法收集2012年1月~2018年6月我院经手术病理证实的IPMN患者24例,均行MRI检查(包括MRI平扫、三期增强以及MRCP),分析IPMNMRI表现、IPMN良恶性因素,并采用ROC曲线分析IPMN肿瘤最大径及胰管扩张直径与肿瘤良恶性关系。结果24例IPMN患者中,良性14例,恶性10例。良性与恶性在性别、肿瘤分型、病变位置间比较,差异无统计学意义(P>0.05);恶性年龄大于良性,差异有统计学意义(P<0.05)。IPMN恶性肿瘤最大径为(55.70±10.73)mm,大于良性的(34.20±7.65)mm,差异有统计学意义(P<0.05);IPMN肿瘤最大径与肿瘤良恶性关系ROC曲线分析得出:曲线下面积(AUC)为0.87,肿瘤最大径最佳临界值为46.40mm,敏感度为85.68%,特异性为83.35%。IPMN恶性主胰管扩张最大径为(8.91±3.22)mm,大于良性的(4.82±1.33)mm,差异有统计学意义(P<0.05);IPMN胰管扩张直径与肿瘤良恶性关系ROC曲线分析得出:AUC为0.88,胰管扩张最大径最佳临界值为7.35mm,敏感度为70.00%,特异性为85.73%。结论MRI能很好显示胰管扩张、囊性病变、管壁内结节等特征,在评估IPMN良恶性中具有敏感性。 Objective To investigate the value of MRI in the differential diagnosis of benign and malignant intraductal papillary mucinous neoplasms (IPMN).Methods 24 patients with IPMN who underwent surgical pathology from January 2012 to June 2018 were enrolled.All patients underwent MRI (including MRI,third-phase enhancement and MRCP),and analyzed IPMN MRI findings and IPMN benign and malignant factors.The ROC curve was used to analyze the relationship between the maximum diameter of the IPMN tumor and the diameter of the pancreatic duct and the benign and malignant tumors.Results Of the 24 patients with IPMN,14 were benign and 10 were malignant.There were no significant differences in benign and malignant gender,tumor classification,and lesion location (P>0.05).Malignant age was greater than benign,the difference was statistically significant (P<0.05).The maximum diameter of IPMN malignant tumor was (55.70±10.73) mm,which was greater than benign (34.20±7.65) mm,the difference was statistically significant (P<0.05).The maximum diameter of IPMN tumor and the relationship between benign and malignant tumors were analyzed by ROC curve: curve The lower area (AUC) was 0.87,the optimal maximum diameter of the tumor was 46.40 mm,the sensitivity was 85.68%,and the specificity was 83.35%.The maximal diameter of malignant main pancreatic duct in IPMN was (8.91±3.22) mm,which was greater than benign (4.82±1.33) mm,the difference was statistically significant (P<0.05).The ROC curve analysis of the relationship between the diameter of pancreatic duct dilatation and the benign and malignant tumors of IPMN It was concluded that the AUC was 0.88,the optimal maximum diameter of the pancreatic duct was 7.35 mm,the sensitivity was 70.00%,and the specificity was 85.73%.Conclusion MRI can show the characteristics of pancreatic duct dilatation,cystic lesions,nodules in the wall,and is sensitive in the evaluation of benign and malignant IPMN.
作者 王召华 李小虎 钱银锋 赵雪梅 王丽娜 朱婉秋 侯唯姝 柏亚 WANG Zhao-hua;LI Xiao-hu;QIAN Yin-feng;ZHAO Xue-mei;WANG Li-na;ZHU Wan-qiu;HOU Wei-shu;BAI Ya(Department of Radiology,the First Affiliated Hospital of Anhui Medical University,Hefei 230022, Anhui,China)
出处 《医学信息》 2019年第14期166-169,共4页 Journal of Medical Information
基金 安徽省高校优秀青年人才支持计划重点项目(编号:gxyqZD 2016054)
关键词 导管内乳头状粘液瘤 胰腺 磁共振成像 Intraductal papillary myxoma Pancreas Magnetic resonance imaging
  • 相关文献

参考文献6

二级参考文献92

  • 1王冬青,纪元,史讯,饶圣祥,叶彤,靳大勇,楼文辉,曾蒙苏.胰腺导管内乳头状黏液肿瘤的CT诊断[J].中华肿瘤杂志,2006,28(8):606-608. 被引量:21
  • 2纪元,朱雄增,楼文辉,王冬青,靳大勇,曾蒙苏,曾海英.胰腺囊性肿瘤92例临床病理分析[J].中华病理学杂志,2007,36(3):160-165. 被引量:11
  • 3Fleisher M, A.M. D, Sturgeon CM, Lamerz R, Witliff JL. Tumor markers: Physiology, Pathobiology, Technology and Clinical Applications. Chicago: AACC press, 2002.32. 被引量:1
  • 4Hyoty M, Hyoty H, Aaran RK, Airo I, Nordback I. Tumour antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma. Eur J Surg 1992,158:173-179. 被引量:1
  • 5Chari ST, Klee GG, Miller LJ, Raimondo M, DiMagno EP. Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. Gastroenterology 2001, 121:640-645. 被引量:1
  • 6Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I, Alhava E. Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma. J Cancer Res Clin Oncol 1994, 120:494-497. 被引量:1
  • 7Shahangian S, Fritsche HA Jr, Hughes JI, Gelder FB. Pancreatic oncofetal antigen and carbohydrate antigen 19-9 in sera of patients with cancer of the pancreas. Clin Chem 1989,35:405-408. 被引量:1
  • 8Fukushima N, Koopmann J, Sato N, Prasad N, Carvalho R, Leach SD, Hruban RH, Goggins M. Gene expression alterations in the non-neoplastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma. Mod Pathol 2005, 18: 779-787. 被引量:1
  • 9Schneider J, Schulze G. Comparison of tumor M2- pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res 2003, 23:5089-5093. 被引量:1
  • 10Rosty C, Christa L, Kuzdzal S, Baldwin WM, Zahurak ML, Carnot F, Chan DW, Canto M, Lillemoe KD, Cameron JL, Yeo CJ, Hruban RH, Goggins M. Identification of hepatocarcinoma- intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 2002,62:1868-1875. 被引量:1

共引文献35

同被引文献29

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部